These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33852815)

  • 1. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing.
    Pasmans CTB; Tops BBJ; Steeghs EMP; Coupé VMH; Grünberg K; de Jong EK; Schuuring EMD; Willems SM; Ligtenberg MJL; Retèl VP; van Snellenberg H; de Bruijn E; Cuppen E; Frederix GWJ
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):413-414. PubMed ID: 33852815
    [No Abstract]   [Full Text] [Related]  

  • 2. Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing.
    Thangavelu T; Wirta V; Orsmark-Pietras C; Cavelier L; Fioretos T; Barbany G; Olsson-Arvidsson L; Pandzic T; Staffas A; Rosenquist R; Levin LÅ
    J Med Econ; 2024; 27(1):1053-1060. PubMed ID: 39101813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early technology assessment of using whole genome sequencing in personalized oncology.
    Simons M; Van De Ven M; Coupé V; Joore M; IJzerman M; Koffijberg E; Frederix G; Uyl-De Groot C; Cuppen E; Van Harten W; Retèl V
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):343-351. PubMed ID: 33910430
    [No Abstract]   [Full Text] [Related]  

  • 4. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
    Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
    BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray.
    Hayeems RZ; Bhawra J; Tsiplova K; Meyn MS; Monfared N; Bowdin S; Stavropoulos DJ; Marshall CR; Basran R; Shuman C; Ito S; Cohn I; Hum C; Girdea M; Brudno M; Cohn RD; Scherer SW; Ungar WJ
    Eur J Hum Genet; 2017 Dec; 25(12):1303-1312. PubMed ID: 29158552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole genome sequencing in oncology: using scenario drafting to explore future developments.
    van de Ven M; Simons MJHG; Koffijberg H; Joore MA; IJzerman MJ; Retèl VP; van Harten WH
    BMC Cancer; 2021 May; 21(1):488. PubMed ID: 33933021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC).
    Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
    J Med Econ; 2020 Oct; 23(10):1123-1129. PubMed ID: 32597288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
    Samsom KG; Bosch LJW; Schipper LJ; Schout D; Roepman P; Boelens MC; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; van Linder BMH; van Deventer K; van den Burg K; Unmehopa U; Rosenberg EH; Koster R; Hogervorst FBL; van den Berg JG; Riethorst I; Schoenmaker L; van Beek D; de Bruijn E; van der Hoeven JJM; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    Nat Protoc; 2024 Mar; 19(3):700-726. PubMed ID: 38092944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.
    van Amerongen RA; Retèl VP; Coupé VM; Nederlof PM; Vogel MJ; van Harten WH
    Ecancermedicalscience; 2016; 10():684. PubMed ID: 27899957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operational models and criteria for incorporating microbial whole genome sequencing in hospital microbiology - A systematic literature review.
    Mintzer V; Moran-Gilad J; Simon-Tuval T
    Clin Microbiol Infect; 2019 Sep; 25(9):1086-1095. PubMed ID: 31039443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical demands to use whole-genome sequencing in precision oncology.
    Meggendorfer M; Jobanputra V; Wrzeszczynski KO; Roepman P; de Bruijn E; Cuppen E; Buttner R; Caldas C; Grimmond S; Mullighan CG; Elemento O; Rosenquist R; Schuh A; Haferlach T
    Semin Cancer Biol; 2022 Sep; 84():16-22. PubMed ID: 34119643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Whole-genome sequencing in German clinical practice : Economic impacts of its use in selected areas of application].
    Plöthner M; Frank M; Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Feb; 60(2):143-150. PubMed ID: 27999872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of whole genome sequencing in German clinical practice.
    Plöthner M; Frank M; von der Schulenburg JG
    Eur J Health Econ; 2017 Jun; 18(5):623-633. PubMed ID: 27380512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.
    van de Ven M; IJzerman M; Retèl V; van Harten W; Koffijberg H
    BMC Med Res Methodol; 2022 Mar; 22(1):83. PubMed ID: 35350994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology.
    Rossen JWA; Friedrich AW; Moran-Gilad J;
    Clin Microbiol Infect; 2018 Apr; 24(4):355-360. PubMed ID: 29117578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
    Caspar SM; Schneider T; Meienberg J; Matyas G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of undetected, clinically relevant chromosome abnormalities when replacing postnatal karyotyping by Whole Genome Sequencing.
    Hochstenbach R; van Binsbergen E; Schuring-Blom H; Buijs A; Ploos van Amstel HK
    Eur J Med Genet; 2019 Sep; 62(9):103543. PubMed ID: 30248410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.
    Samsom KG; Schipper LJ; Roepman P; Bosch LJ; Lalezari F; Klompenhouwer EG; de Langen AJ; Buffart TE; Riethorst I; Schoenmaker L; Schout D; van der Noort V; van den Berg JG; de Bruijn E; van der Hoeven JJ; van Snellenberg H; van der Kolk LE; Cuppen E; Voest EE; Meijer GA; Monkhorst K
    J Pathol; 2022 Oct; 258(2):179-188. PubMed ID: 35792649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer.
    Simons MJHG; Uyl-de Groot CA; Retèl VP; Mankor JM; Ramaekers BLT; Joore MA; van Harten WH
    Value Health; 2023 Jan; 26(1):71-80. PubMed ID: 35973926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.
    Christensen KD; Vassy JL; Phillips KA; Blout CL; Azzariti DR; Lu CY; Robinson JO; Lee K; Douglas MP; Yeh JM; Machini K; Stout NK; Rehm HL; McGuire AL; Green RC; Dukhovny D;
    Genet Med; 2018 Dec; 20(12):1544-1553. PubMed ID: 29565423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.